Liver disease Patients' vaccine response under the microscope
NCT ID NCT05669677
First seen Apr 14, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study looked at how well COVID-19 vaccines protect people with chronic liver disease, including hepatitis B, C, NAFLD, and NASH. Researchers followed 233 adults for 6 months, checking their immune response through blood tests and questionnaires. The goal was to see if liver disease severity affects vaccine effectiveness and to track COVID-19 infections in this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.